NCT07900230Not yet recruiting
The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain
Rationale and Design of the GEIR Registry: a Nationwide Multicentre Study of the Natural History, Epidemiological, Neurovascular, Imaging and Therapeutic Aspects of Retinal Stroke in Spain
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
Retinal stroke is a time-dependent neurovascular emergency associated with severe visual loss, increased risk of cerebrovascular events and substantial variability in clinical management. The GEIR Registry is a nationwide, multicentre, ambispective observational registry comprising retrospective and prospective data collected from participating hospitals throughout Spain.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Germans Trias i Pujol Hospital
- Diseases
- Stroke
- NCT number
- NCT07900230
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jan 2027 to the primary completion date, 1 Jan 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with others diseases affecting retinal examination or retinal behaviour
Who the study is looking for
- Age \>18 years.
- Clinical diagnosis of retinal stroke.
- Symptom onset or last known normal vision within the previous 24 hours.
- Absence of pre-existing ocular pathology severely limiting visual acuity in the affected eye.
- \-
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.